

The potential connection between molecular changes and biomarkers related to ALS and the development and regeneration of CNS

Glavač, Damjan; Mladinić, Miranda; Ban, Jelena; Mazzone, Graciela L; Sámano, Cynthia; Tomljanović, Ivana; Jezernik, Gregor; Ravnik-Glavač, Metka

Source / Izvornik: **International Journal of Molecular Sciences, 2022, 23, 1 - 18**

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.3390/ijms231911360>

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:193:689981>

Rights / Prava: [Attribution 4.0 International](#)/[Imenovanje 4.0 međunarodna](#)

Download date / Datum preuzimanja: **2024-12-24**

Repository / Repozitorij:



[Repository of the University of Rijeka, Faculty of Biotechnology and Drug Development - BIOTECHRI Repository](#)





Review

The Potential Connection between Molecular Changes and Biomarkers Related to ALS and the Development and Regeneration of CNS

Damjan Glavač^{1,2,†}, Miranda Mladinić^{3,†}, Jelena Ban³, Graciela L. Mazzone⁴, Cynthia Sámano⁵, Ivana Tomljanović³, Gregor Jezernik² and Metka Ravnik-Glavac^{6,*}

- ¹ Department of Molecular Genetics, Institute of Pathology, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia
 - ² Center for Human Genetics & Pharmacogenomics, Faculty of Medicine, University of Maribor, 2000 Maribor, Slovenia
 - ³ Laboratory for Molecular Neurobiology, Department of Biotechnology, University of Rijeka, 51000 Rijeka, Croatia
 - ⁴ Instituto de Investigaciones en Medicina Traslacional (IIMT), CONICET-Universidad Austral, Buenos Aires B1629AHJ, Argentina
 - ⁵ Departamento de Ciencias Naturales, Universidad Autónoma Metropolitana Unidad Cuajimalpa, Mexico City 05348, Mexico
 - ⁶ Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia
- * Correspondence: metka.ravnik-glavac@mf.uni-lj.si
† These authors contributed equally to this work.



Citation: Glavač, D.; Mladinić, M.; Ban, J.; Mazzone, G.L.; Sámano, C.; Tomljanović, I.; Jezernik, G.; Ravnik-Glavac, M. The Potential Connection between Molecular Changes and Biomarkers Related to ALS and the Development and Regeneration of CNS. *Int. J. Mol. Sci.* **2022**, *23*, 11360. <https://doi.org/10.3390/ijms231911360>

Academic Editors: Ana Lloret and Ana Cervera

Received: 26 July 2022

Accepted: 22 September 2022

Published: 26 September 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Neurodegenerative diseases are one of the greatest medical burdens of the modern age, being mostly incurable and with limited prognostic and diagnostic tools. Amyotrophic lateral sclerosis (ALS) is a fatal, progressive neurodegenerative disease characterized by the loss of motoneurons, with a complex etiology, combining genetic, epigenetic, and environmental causes. The neuroprotective therapeutic approaches are very limited, while the diagnostics rely on clinical examination and the exclusion of other diseases. The recent advancement in the discovery of molecular pathways and gene mutations involved in ALS has deepened the understanding of the disease pathology and opened the possibility for new treatments and diagnostic procedures. Recently, 15 risk loci with distinct genetic architectures and neuron-specific biology were identified as linked to ALS through common and rare variant association analyses. Interestingly, the quantity of related proteins to these genes has been found to change during early postnatal development in mammalian spinal cord tissue (opossum *Monodelphis domestica*) at the particular time when neuroregeneration stops being possible. Here, we discuss the possibility that the ALS-related genes/proteins could be connected to neuroregeneration and development. Moreover, since the regulation of gene expression in developmental checkpoints is frequently regulated by non-coding RNAs, we propose that studying the changes in the composition and quantity of non-coding RNA molecules, both in ALS patients and in the developing central nervous (CNS) system of the opossum at the time when neuroregeneration ceases, could reveal potential biomarkers useful in ALS prognosis and diagnosis.

Keywords: amyotrophic lateral sclerosis; ALS-related genes; CNS development; neuroregeneration; peripheral biomarkers; non-coding RNAs

1. Introduction

Amyotrophic lateral sclerosis (ALS), also called Lou Gehrig's disease, is a complex and genetically heterogeneous neurodegenerative disorder characterized by progressive muscle paralysis reflecting the degeneration of motor neurons (MNs) in the primary motor cortex, corticospinal tract, brainstem, and spinal cord [1]. Particularly, ALS affects lower MNs

in the spinal cord and brainstem and upper MNs in the motor cortex [2]. This neuronal degeneration leads to progressive skeletal muscle atrophy and death by respiration failure after 2–5 years from the onset of symptoms [3]. The disease, presenting in middle age, has an incidence of 2 per 100,000 persons per year. The familial ALS forms represent only around 5% of cases, while the majority of cases are sporadic forms, which are mostly phenotypically indistinguishable from familial forms, suggesting the involvement of common pathophysiological pathways. Numerous studies have been focused on revealing the variety of neurodegenerative processes underlying ALS, including oxidative stress, mitochondrial impairment, excitotoxicity, alteration in the Ca^{2+} homeostasis, mitochondrial dysfunction, growth factor deficiency, defective axonal transport, disrupted proteostasis, and RNA metabolism [4–8], involving both neuronal and non-neuronal cells [9]. Indeed, ALS is a multifactorial disease with diverse etiology and pathogenesis, and suspected immune-mediated mechanisms remain, however, controversial [10].

Currently, there is no definitive therapy, and the drugs approved for ALS treatment, Riluzole and Edaravone, provide only modest benefits and only in some patients [11,12]. Recently, promising new therapeutic approaches for the treatment of ALS have emerged, including gene therapy and cell therapy. ALS-directed gene therapeutic strategies include antisense oligonucleotides, RNA interference, CRISPR, adeno-associated virus (AAV)-mediated trophic support, and antibody-based methods, some of which have reached human clinical trials [13]. To develop safe therapeutic strategies, it is of major importance to consider the normal functions of the manipulated genes and the potential contribution of gene loss-of-function to ALS [14]. In restorative approaches using transplanted stem cells or neural progenitor cells, the major problem considers the complexity of the functional networks required to produce walking, which is produced via a complex developmental program that is inactivated in adulthood [15].

Both the diagnosis and treatment of the disease are currently insufficient, primarily due to deficient knowledge of genetic and molecular causes of the disease as well as pathological pathways involved in the disease progression. Here, we propose a possible connection of ALS with neuroregeneration and aberrant early central nervous system (CNS) development [16,17], where the complex pathophysiology could be orchestrated by several non-coding RNAs that also could present potentially useful biomarkers in ALS prognosis and diagnosis. Moreover, the miRNA and lncRNA molecules known to control the expression of the ALS-related genes of interest have been co-located both in the peripheral blood of ALS patients, as well as in brain and spinal cord tissues [18,19], giving a strong indication of possible involvement and importance in the control of both CNS development and ALS pathophysiology.

2. Genetics of ALS

Although there is not a final criterion for familial ALS, the general agreement is accepted that the presence of the disease in first-or second-degree relatives represents a family disease [20]. Many familial types of ALS have a classic pattern of Mendelian inheritance, mainly in an autosomal-dominant manner with a high degree of penetration. However, cases of recessive and X-linked recessive inheritance are also described [21]. In 1989, the first gene locus on chromosome 21 (*ALS1*), which is associated with a dominant type of familial ALS, was discovered [22]. On this locus, the *SOD1* gene and numerous mutations in it in connection with ALS were later identified [23]. The ALS disease is related to many different genes and already more than 150 genes are currently described in the accessible ALSod database (<http://alsod.iop.kcl.ac.uk/>) (accessed on 1 July 2022). However, the vast majority of mutations in these genes were discovered in connection with the disease in individual cases; therefore, those are currently classified only as candidate genes. On the other hand, the changes in only four genes, *SOD1* [23], *FUS* [24,25], *TARDBP* [7,26,27], and *C9orf72* [28,29], represent a high risk for the development of ALS, which has been confirmed by numerous studies. The *FUS* and TDP-43 mutations were connected with nuclear transport and the metabolism of RNA. Mutations in genes *SOD1*, *TARDBP* (TDP-43), and

FUS together occur in 20–30% of the familial type of the disease [30], and mutations in the *SOD1* gene alone affect up to 20% of patients with the autosomal dominant type of familial ALS and 2% of patients with the sporadic type of ALS [31]. In hereditary types, the mutation, which causes the disease, is detected in approximately two-thirds of patients and only in about 11% of patients with the sporadic type [32,33]. Sporadic types may be caused by mutations with low penetration, de novo mutations, different genetic variations, and epigenetic events [34]. Clinically, sporadic and familial types do not distinguish between each other, but in comparison with sporadic, the familial type of the disease occurs at an earlier age of life [35], approximately a decade before the sporadic type [31], lasts longer, and women and men get ill with the same frequency [35,36]. Up to 50% of all patients with ALS also express symptoms of frontotemporal dementia (FTD), which leads to the degradation of neurons in frontotemporal brain lobes [37]. Interestingly, it was discovered that some of the ALS-specific genes, *UBQLN2* [21] and *C9orf72* [28,29], are responsible for the combination of ALS-FTD [38]. The discovery of the involvement of *C9orf72* in the year 2011 represented a new milestone in the research because it is one of the most common genetic causes of the disease's development. The expansion of hexanucleotide (GGGGCC) repeats in the first intron of *C9orf72* is not only one of the most common mutations in connection with ALS but also the second most common in FTD cases [39]. In addition, this discovery strengthened the hypothesis that the pathogenesis of ALS is carried out by several different genetic and molecular pathways [4]. Some of the less-frequently mutated genes associated with ALS, of which some are also linked to other neurodegenerative diseases, include *OPTN* [40], *VCP* [28,41,42], *SQSTM1* [43], *FIG4* [44], *ATXN2* [45], *DAO* [46], *SPG11* [47], *PFN1* [48], *VAPB* [49], *ALS2* [50], *SETX* [51], and *ANG* [52]. Recently, a link between the haploinsufficiency of *TBK1* and ALS has also been discovered [53], and a kinesin family member gene (*KIF5A*) was recognized as a novel gene associated with ALS [54,55] as well as a new ALS risk gene *C21orf2* [56] and 15 risk loci with different genetic architecture and neuron-specific biology [16]. Moreover, in patients with ALS, some studies have shown the changing patterns of methylation in ALS-related genes [57–59] and connected the engagement of the epigenetic mechanisms in motor neuron apoptotic cell death through DNA methylation, which is essential during the development of the nervous system and could be relevant to human ALS pathobiology [60]. The results of several studies suggest that epigenetic changes (through methylation and noncoding RNAs) may represent new biomarkers and contribute to the development of new ALS therapies (reviewed in [61–63]). Moreover, we propose that the overlap and correlation in the expression of the selected biomarkers during early CNS development and in ALS patients could narrow down the number of potential candidates, as well as open new insights into disease pathogenesis.

3. MiRNA and lncRNA Controlling ALS

The expression of genes depends on several different processes including variations in coding DNA sequences and the expression of non-coding RNAs (miRNAs, lncRNAs).

MiRNAs are a class of small, single-stranded, non-coding RNAs that play important roles in gene-regulation by targeting mRNAs for cleavage or translational repression [64]. Since each miRNA can regulate up to hundreds of mRNA targets, it is possible that the transcriptome alterations detected in ALS patients derive, at least partially, from the disruption of miRNA networks. Indeed, studies using miRNA microarrays or RNA deep sequencing have revealed extensive changes in the expression of more than a hundred miRNAs in ALS [18,19,65–68]; however, the detection of the precise roles of specific miRNAs and/or combinations of miRNAs for the development of disease-specific biomarkers is a focus of current research [69,70]. In current review studies, more commonly detected deregulated miRNAs associated with ALS have been collected and include let-7b, miR-9, miR-16-5p, miR-124a, miR-128, miR-132, miR-133b, miR-143, miR-451, miR-181, miR-183, miR-206, miR-338-3p, and miR-638 [18,19,71–73]. However, data on miRNAs as biomarkers in ALS are sometimes contradictory and currently still not clear enough for translation into clinical practice.

LncRNAs are RNA transcripts greater than 200 nucleotides that lack an open reading frame and have little coding potential. Although the functions of the vast majority of lncRNA transcripts remain unknown, it is assumed that they are possible regulators of biogenesis, cellular cycles, and differentiation, and are involved in nervous system development and neurological diseases [74]. LncRNAs can act both as the epigenetic regulators of target genes and as components of an extensive, unexplored network of interacting RNAs involving miRNAs and mRNAs.

The roles of lncRNA in ALS have just started to be explored and a small number of lncRNAs associated with ALS demonstrate that there is still much to do to identify and understand their role in ALS [75]. The RNA-seq analyses of sALS and fALS patients revealed the presence of lncRNAs differentially expressed both in blood mononuclear cells and in the spinal cord, including *NEAT1*, *MALAT1*, and *MEG3* [76–78]. In the study of Yu et al., lnc-DYRK2-7: 1 and lnc-POTEM-4: 7 were specifically down-regulated in affected subjects compared to healthy controls [79].

4. Novel ALS GWAS Risk Loci and Their Connection with CNS Development and Neuroregeneration

It is very likely that there are multiple genetic alterations on different genomic regions that carry information for the coding and non-coding RNAs necessary for the emergence of complex diseases. Thus, a complex cross-ancestry genome-wide association study (GWAS) was recently performed, combined with whole-genome sequencing and a large cortex-derived expression quantitative trait locus dataset. The data revealed 15 ALS-associated risk loci and the related genes, indicating perturbations in vesicle-mediated transport and autophagy and cell-autonomous disease initiation in glutamatergic neurons [16] (Table 1).

Table 1. List of the genes related to the 15 risk loci in ALS identified through the common and rare variant association analyses [16].

Gene	ID (GenBank)
<i>SOD1</i>	6647
<i>C9orf72</i>	203228
<i>NEK1</i>	4750
<i>PTPRN2</i>	5799
<i>FUS</i>	2521
<i>COG3</i>	83548
<i>ERGIC1</i>	57222
<i>TARDBP</i>	23435
<i>TBK1</i>	29110
<i>OPTN</i>	10133
<i>SLC9A8</i>	23315
<i>SPATA2</i>	9825
<i>GPX3</i>	2878
<i>TNIP1</i>	10318
<i>CFAP410</i>	755
<i>KIF5A</i>	3798
<i>MOBP</i>	4336
<i>RPSA</i>	3921
<i>SCFD1</i>	23256
<i>UNC13A</i>	23025

Neuroregeneration is a complex process, influenced by numerous cellular and molecular mechanisms, yet not fully understood. Understanding why neuroregeneration fails in the adult mammalian CNS would give the possibility to alter the key pathways to promote cell survival and axon regeneration and possibly alter the outcome of neurodegenerative diseases, including ALS [80]. The comprehensive analysis of the proteins that change during the early developmental period when neuroregeneration in CNS stops being possible revealed the abundance of the proteins related to neurodegenerative diseases, including

the proteins coded by the genes related to the ALS risk loci [17]. Those results connect ALS with neurodevelopment and neuroregeneration, with the possible identification of new diagnostic and therapeutic targets.

5. Studying Neuroregeneration in Opossum *Monodelphis domestica*

One of the major challenges of modern neurobiology concerns the inability of the adult mammalian CNS to regenerate and repair itself after injury or after neuronal loss in neurodegenerative diseases, although new therapies supporting compensation mechanisms could give alternative solutions. It is still unclear why the ability to regenerate the CNS is lost during evolution and development and why it becomes very limited in adult mammals. A convenient model to study the cellular and molecular basis of this loss is the neonatal opossum (*Monodelphis domestica*). Opossums are marsupials that are born very immature with the unique possibility to successfully regenerate the postnatal spinal cord after injury in the first two weeks of their life, after which this ability abruptly stops at 14 days in cervical spinal segments and at 17 days in less mature lumbar spinal segments [81]. Thus, neonatal opossums represent a unique opportunity to achieve and study mammalian CNS that can regenerate, without the need for the invasive intrauterine surgery of pregnant females (as is necessary for other mammalian laboratory animals, such as mice or rats). In addition, the tiny neonatal opossum CNS can be maintained in culture in its entirety and this preparation is similar to the intact animal in its ability to regenerate [82]. Moreover, in isolated preparations, reflex activity and neurogenesis continue, and the structure remains normal in appearance, with minimal cell death [83].

Even though our understanding of molecular and cellular mechanisms that promote or inhibit neuronal regeneration is expanding [84], it is still unclear what are the key differences between the neuronal systems that can and cannot regenerate and how they can be manipulated to revert the outcome. For reasons yet unknown, with development and age, the mammalian CNS loses its capacity for functionally relevant repair after injury, as is observed on the evolutionary scale [81]. Although the CNS is more plastic early after birth than in the adult, the postnatal mammalian CNS usually displays limited regenerative capacities, and the precise cellular and molecular basis for this developmental loss are mostly unclear. In the short-tailed gray opossum, *Monodelphis domestica*, newly born animals correspond roughly to 12-day mouse or rat embryos [85], and they have the ability to fully functionally regenerate the cervical spinal cord until the postnatal day 12, while in the less-mature lumbar segments, regeneration continues until postnatal day 17, approximately [86]. Thus, opossums represent the unique opportunity to achieve and study mammalian CNS that can regenerate without the need for intrauterine surgery on pregnant mothers. In previous studies [87,88], differentially expressed genes were identified in opossum spinal cords during the critical period of development when regeneration stops being possible, revealing the molecules involved in nucleic acid management, protein synthesis and processing, the control of cell growth, structure and motility, cell signaling, extracellular matrix molecules, and their receptors. The transcriptomic data were upgraded with proteomic research [17], to select the overlapping molecules as the most promising candidates controlling regeneration, to be tested in functional studies.

6. ALS-Related Proteins Change in Opossum Spinal Cord When Regeneration Ceases

Among the proteins that are differentially distributed in opossum spinal tissue that can and cannot regenerate after injury, we identified the numerous proteins related to neurodegenerative diseases, such as Huntington's, Parkinson's, and Alzheimer's disease [17]. Interestingly, the ALS-related proteins were detected, among which were those connected to the 15 risk loci linked to ALS [16] (Table 2). Several proteins are present uniquely in the regenerating spinal cord tissue taken from 5-day-old opossums (P5), while the others are conversely present only in the non-regenerating opossum tissue taken from the older animals (P18). Moreover, we have found different ALS-related proteins to be present in

both regenerating (P5) and non-regenerating (P18) spinal cords, but to a dissimilar degree. Their functional classification is shown in Figure 1.

To our knowledge, this is the first time that the ALS-related genes or proteins have been found to change their expression during the early postnatal development in mammalian spinal cord tissue during the checkpoint when neuroregeneration ceases to be possible. These results indicate that the proteins related to ALS, and in general to neurodegeneration in aged CNS, could have an important physiological role during postnatal neurodevelopment, particularly that they could be involved in the molecular and cellular mechanisms underlying neuroregeneration [89].

Table 2. Proteins related to ALS and detected by mass spectrometry as differentially distributed in P5 and P18 opossum spinal cords.

Proteins unique for P5 spinal cords	ID	Gene symbol	LFQ Intensity
Nuclear assembly factor 1 ribonucleoprotein	K7E2M8	<i>TNIP1/NAF1</i>	1.24×10^7
Kinesin family member 15	F6S782	<i>KIF15</i>	8.6×10^6
Cilia- and flagella-associated protein	F6R525	<i>CFAP20</i>	7.45×10^6
Component of oligomeric Golgi complex 4	F6T7R4	<i>COG4</i>	1.64×10^7
Proteins unique for P18 spinal cords			
Tau tubulin kinase 1	F7FPA7	<i>TBK1</i>	7.2×10^6
Unc-13 homolog A	F6W9P5	<i>UNC13A</i>	1.85×10^7
Component of oligomeric Golgi complex 1	F7F869	<i>COG1</i>	8.05×10^6
Component of oligomeric Golgi complex 2	F6ZMV7	<i>COG2</i>	5.2×10^7
Component of oligomeric Golgi complex 5	F7ERT4	<i>COG5</i>	6.9×10^6
Component of oligomeric Golgi complex 7	F7BTD1	<i>COG7</i>	1.4×10^7
Protein tyrosine phosphatase, receptor type T	F7GH48	<i>PTPRT</i>	1.71×10^7
Protein tyrosine phosphatase, receptor type N	F6RCL7	<i>PTPRN</i>	6.7×10^7
Protein tyrosine phosphatase, receptor type M	F6ZQ35	<i>PTPRM</i>	4.25×10^6
Proteins up-regulated in P5 spinal cords	ID	Gene symbol	Fold change
Sec1 family domain containing 1	F7BSJ8	<i>SCFD1</i>	1.14
40S ribosomal protein SA	F7BC17	<i>RPSA</i>	1.43
ERGIC and Golgi 3	F6WZ15	<i>ERGIC3</i>	3.63
FUS RNA binding protein	F6WGL5	<i>FUS</i>	1.7
Kinesin family member 1B	F7EJI5	<i>KIF1B</i>	1.31
Kinesin-like protein	F7GBT8	<i>KIF5C</i>	1.02
Kinesin light chain 2	F7B8A8	<i>KLC2</i>	1.07
Kinesin light chain 4	F7FP03	<i>KLC4</i>	1.42
Kinesin family member 21B	F7A9R7	<i>KIF21B</i>	1.11
Proteins up-regulated in P18 spinal cord			
Superoxide dismutase (Cu-Zn)	F6VK78	<i>SOD1</i>	1.53
Cyclin G-associated kinase	F7CA71	<i>GAK</i>	1.23
Optineurin	F6R1Z3	<i>OPTN</i>	1.49
Kinesin family member 1A	F6PG86	<i>KIF1A</i>	1.04
Kinesin-like protein	F6Y7G9	<i>KIF2A</i>	1.28
Kinesin-like protein	F6SD95	<i>KIF3A</i>	1.27
Kinesin-like protein	F6RWN1	<i>KIF3B</i>	1.35
Kinesin-like protein	F7BJ22	<i>KIF5B</i>	1.05
Kinesin-associated protein 3	F7GBK2	<i>KIFAP3</i>	1.33
Glutathione peroxidase	F7CS77	<i>GPX1</i>	1.01
Component of oligomeric Golgi complex 6	F6SS12	<i>COG6</i>	1.02
Protein tyrosine phosphatase, receptor type D	F6S1W5	<i>PTPRD</i>	1.2
Protein tyrosine phosphatase, receptor type G	F6Z7H9	<i>PTPRG</i>	1.77
Protein tyrosine phosphatase, receptor type Z1	F6ZVL3	<i>PTPRZ1</i>	2.8
Receptor-type tyrosine-protein phosphatase	F7G6B6	<i>PTPRA</i>	1.73

We have found some of the most well-characterized ALS high-risk factors, such as SOD1 and OPTN proteins, to be upregulated in non-regenerating (P18) opossum spinal cords, unlike FUS, which was upregulated in regenerating (P5) opossum spinal cords (Table 2). TBK-1 was found to be uniquely expressed in P18 spinal cords. The time course of their expression during postnatal CNS development in marsupials such as *M. domestica* remains largely unexplored. Further, UNC13A (or Munc13-1 in mammals), another ALS-related protein [16,90,91], was expressed exclusively in the P18 opossum spinal cord (Table 2). UNC13A is essential for synaptic vesicle maturation during exocytosis as a target of the diacylglycerol second messenger pathway and for the neurotransmitter release of most glutamatergic but not inhibitory GABA-mediated synapses [92,93]. Its unique expression in the P18 spinal cord correlates with the developmental stage at which the neurogenesis is almost completed [94] and newly generated neurons have to establish and consolidate their synaptic connections with other neurons.




Figure 1. Cont.




Figure 1. Functional classification of the proteins identified by MS as differentially distributed in the opossum P5 and P18 spinal cords. Proteins were classified based on assumed molecular function (A), biological process (B), or protein class (C).

7. KIF5A and Kinesin Family Member Proteins Expressed in Developing Opossum Spinal Cord

Neurons are highly polarized cells with neurites that can extend over long distances from soma. Axonal transport is fundamental during neuronal development as well as in mature neurons, allowing efficient intra- and intercellular communication [95,96]. Kinesins are microtubule-based motor proteins that play a central role in the axonal transport of several cargos including organelles such as mitochondria, neurofilaments, receptors for neurotransmitters including glutamate [97], and granules containing both RNA and RNA-binding proteins [55].

KIF5A, KIF5B, and KIF5C are mammalian heavy chain isoforms that belong to the Kinesin-1 family and all are expressed in neurons [95,98]. *KIF5A* was recently identified as a novel ALS gene [16,54,55]. Missense mutations of *KIF5A* cause the defective anterograde transport of cargo along dendrites and axons. Deficiency in *KIF5A* expression and cargo binding has been associated with the accumulation of phosphorylated neurofilaments and amyloid precursor proteins within neuronal cell bodies, and subsequent neurodegeneration, in patients with multiple sclerosis [55].

The proteome analysis of the developing opossum spinal cord revealed 12 kinesins or kinesin-like proteins (Table 2). For instance, KIF5C was found to be up-regulated in P5 spinal cords, while KIF5B was up-regulated in P18 spinal cords. These expression profiles are in agreement with *KIF5* expression in 2-week-old mice since both KIF5B and KIF5C were up-regulated in axon-elongating neurons, with KIF5C highly enriched in lower motor neurons [98]. KIF5B is expressed in glial cells [98], and this further confirms the correlation between the onset of gliogenesis in P18 opossums [94] and its upregulation.

In addition to Kinesin-1 family members, KIF1B, KLC2, KLC4, and KIF21B were up-regulated in P5 spinal cords, while KIF1A, KIF2A, KIF3A, KIF3B, and KIFAP3 were up-regulated in the P18 spinal cord. KIF15 was found to be unique in the P5 opossum spinal cord. This observation is in agreement with its co-localization with microtubules in dendrites and in growth cones, in particular in migratory neurons [99], because at that developmental stage (P5), extensive neurogenesis occurs in the opossum CNS [94,100].

8. NEK1 and CFAP410 and Interacting/Related Partners

NEK1 and *CFAP410* were identified as ALS risk factors/loci in humans (Table 1) [16,101,102]. The protein encoded by *NEK1* is involved in cell-cycle regulation [103], essential during the transition from the proliferative (undifferentiated) state of neuronal progenitors to the post-mitotic (differentiated) state of neurons. The proteomic analysis of the opossum P5 and P18 spinal cord proteome did not identify proteins encoded by the *NEK1* gene. However, NIMA-related kinase 9 (Nek9), a member of the same family of serine/threonine protein kinases involved in mitosis [104], was identified as unique to the P18 opossum spinal cord.

MAP2K1, encoding for mitogen-activated protein kinase 1, is an important paralog of *NEK1*. *MAP2K1* was identified in both P5 and P18 opossums, with higher expression in P18 (1.08 times more). We have recently shown [105] that both MAPK/p38 and JNK/c-Jun signaling pathways are involved during neurite outgrowth and neuronal network formation as well as during regeneration after injury through the interaction and induction of activating transcription factor 3 (ATF3) [106,107].

Kinesin-1 adapter fasciculation and elongation protein zeta 1 (FEZ1), known to be found in the centrosomal complex with *NEK1* and involved in axonal development [108], was found to be expressed only in P5 opossums (LFQ intensity 5.6×10^6).

In addition to the cell cycle, *NEK1* is also involved in cilia formation and maintenance as well as in the regulation of cell morphology and cytoskeletal organization [103,104] and is in direct interaction with *CFAP410*, another ALS risk factor [16,109]. Proteomic analysis in opossums did not reveal it, but cilia- and flagella-associated protein 20 (*CFAP20*), with a mainly unknown function, was found to be unique to P5 (Table 2). Moreover, *NEK1* is a direct interacting partner with *KIF3A* (upregulated at P18), in which dysfunction induces developmental defects in neuronal migration and differentiation, delays in neural stem cell-cycle progression, and failures in interkinetic nuclear migration [110].

These data strongly indicate that common pathways are involved in both development, regeneration, and degeneration. Being unique to P5 opossums (equivalent to E16 mice or E18.5 rat embryos [85]), *FEZ1* and *CFAP20* expression confirms their involvement in early CNS, with ongoing neurogenesis. It is striking that the time when neuroregeneration ceases in the opossum spinal cord [82,86] overlaps with the switch from neurogenesis to gliogenesis, once the formation of the six-layered cortex is accomplished, between P18 and P20 [94]. This fact could be in connection with the discovery that ALS is a cell-autonomous disease with initiation in glutamatergic neurons [16]. For example, the *UNC13A*, uniquely expressed in the P18 opossum spinal cord, could be involved in or responsible for perturbation in glutamatergic neurotransmission, in addition to dysfunctions in kinesin-mediated transport [111,112].

9. Could Neurodegeneration Be Considered a Failure of Neuroregeneration?

Common ALS-related genes/proteins identified in [16] (Table 1) and in the proteome analysis of developing opossum spinal cord [17] (Table 2) are summarized in Figure 2. It is still to be tested if the ALS-related genes/proteins have an impact on neuronal regeneration. Particularly, it is to be studied if the neurodegeneration could be considered as a failure of neuroregeneration [113] and possibly as the regress of injured neurons to an embryonic or early postnatal transcriptional growth state [114]. The supporting evidence for this point of view has been found from recent investigations, where induced pluripotent stem cells (iPSCs) or induced neurons (iNs) that were derived from AD patients showed a de-differentiated phenotype, reminiscent of an immature (i.e., progenitor-like) neuronal state. These cells also show signs of a cell cycle re-entry [115,116]. These observations suggest that the process of de-differentiation in response to injury represents the link between neuronal degeneration, development, and regeneration and this might apply to ALS as well.




Figure 2. Matching genes/proteins identified through the common and rare variant association analyses from ALS patients [16] and the proteomic analysis of developing opossum spinal cord [17].

10. Do the Same Non-Coding RNAs Control Neuroregeneration and ALS-Related Neurodegeneration?

The non-coding RNAs are known to have an important role in controlling CNS axon regeneration [117] and neurogenesis [118], but also neurodegeneration [119,120]. Thus, it would be of great interest to understand if the non-coding RNAs that control the expression of ALS-related genes might have a role in neuroregeneration. Particularly, it would be interesting to reveal if they change their expression during the developmental period when neuroregeneration in the mammalian spinal cord stops being possible. The construction of an mRNA–miRNA–lncRNA network that would contain the overlapping molecules that have a role both in ALS pathobiology and also in early CNS development and in neuroregeneration and neurodegeneration, would open the scenario for narrowing down the potential candidates for ALS-detecting biomarkers and also give new insight into the molecular basis of ALS, with the possibility of the early diagnosis of the disease in childhood.

In Supplementary Table S1, we have listed the ALS marsupial-related genes from Table 2 and up to five of their most-predicted interacting human miRNA and lncRNA molecules, indicating their expression in the blood, muscles, and spinal cord. In addition, in Table 3, we specifically collected, from Supplementary Table S1, those human miRNAs that potentially control the expression of genes that code proteins differentially distributed in P5 and P18 opossum spinal cords and which have already been reported to be dysregulated in ALS patients.

It is striking that not only the genes coding the ALS-related proteins are both present in the peripheral blood of ALS patients and in the opossum spinal cord, but also their interacting miRNA and lncRNA molecules, making them strong candidates for ALS biomarkers (Supplementary Table S1, Table 3, and Figure 3). Several of those molecules have already been recently connected to neuroregeneration. For example, the downregulation of the hsa-miR-124-3p, which is related to KIF1B and PTPRZ1 (Table 3 and Figure 3), is known to promote the neural stem activation through the activation of Wnt/ β -catenin signaling in spinal cord neural progenitor cells [121], having beneficial effects on neuroregeneration [122]. Next, the hsa-miR-200c-3p, related to PTPRD and TBK1 (Table 3 and Figure 3), was found to be a key factor that promotes successful spinal cord regeneration in axolotls, regulating the stem cell identity [123]. The hsa-miR-21-5p, related to KIFAP3, was recently shown to be involved in the promotion of structural and functional recovery in sciatic nerve injury [124]. The hsa-miR-222-3p, related to COG2, KIF5C, and KIF3B (Supplementary Table S1, Table 3, and Figure 3) enhanced the neuronal differentiation of neural stem cells and thus the combination of nanofibrous scaffolds with miR-222 is proposed as a promising

Table 3. miRNAs that regulate the expression of genes that code proteins differentially distributed in P5 and P18 opossum spinal cords and detected in association with ALS. (data from miRTarBase (<https://miRTarBase.cuhk.edu.cn/>) (accessed on 1 July 2022) and [18,19,71–73]).

miRNA	Genes
hsa-miR-1-3p	<i>GAK, KIF2A, KIF5B, PTPRD</i>
Let-7b-5p	<i>ERGIC3, KIF2A</i>
hsa-miR-10a-5p	<i>PTPRT, KIF3B</i>
hsa-miR-9-5p	<i>OPTN, KIF1A, KIF1B</i>
hsa-miR-16-5p	<i>PTPRT, RPSA, KIF1B, KIF2A, KIF3B</i>
hsa-miR-18a-3p	<i>PTPRN, COG4</i>
hsa-miR-21-5p	<i>KIFAP3</i>
hsa-miR-26-5p	<i>KIF1B, KIF21B, UNC13A</i>
hsa-miR-34a-5p	<i>KIF2A, KIF5B</i>
hsa-miR-92a-3p	<i>KLC2, GAK, OPTN</i>
hsa-miR-124-3p	<i>KIF1B, PTPRZ1</i>
hsa-miR-149-5p	<i>COG1, KIF1A</i>
hsa-miR-155-5p	<i>KIF3A, COG2</i>
hsa-miR-181a-5p	<i>TNIP1/NAF, PTPRZ1</i>
hsa-miR-183-3p	<i>KIF5C, KIF2A</i>
hsa-miR-186-5p	<i>COG2, SCFD1</i>
hsa-miR-192-5p	<i>KIF5B, KIF15</i>
hsa-miR-193b-3p	<i>KIF15, KIF1B, PTPPG</i>
hsa-miR-197-3p	<i>SOD1, FUS</i>
hsa-miR-200c-3p	<i>PTPRD, PTPRZ1, TBK1</i>
hsa-miR-206	<i>SOD1</i>
hsa-miR-218-5p	<i>KIF15, KIF21B</i>
hsa-miR-221-3p	<i>TNIP1/NAF, TBK1</i>
hsa-miR-331-3p	<i>FUS, KLC2, PTPRT</i>
hsa-miR-335-5p	<i>PTPRT, PTPRM, KLC4, OPTN, PTPRA</i>
hsa-miR-615-3p	<i>COG4, RPSA, FUS</i>

For the other non-coding RNA molecules listed in Supplementary Table S1, the role in neuroregeneration and CNS development is still to be studied, determining their usefulness as eventual ALS biomarkers.

The long non-coding RNA molecules are very little known in marsupials, especially in *Monodelphis domestica*. Even though the lncRNAs are widely expressed, their low conservation at the sequence level makes the revelation of their evolutionary history often challenging [130]. However, marsupials contain the paraspeckles, nuclear bodies that in human and mouse cells are assembled around an architectural NEAT1/MENe/b lncRNA, which are tissue-specific, stress-responding nuclear bodies, illustrating their structural and functional continuity over 200 million years of evolution throughout the mammalian lineage [130].

RNA network visualization was performed using the software package CytoScape 3.8.2. [131] using default CytoScape settings and freely available style options.

11. Future Perspectives and Conclusions

There is an urgent need for biomarkers useful for the diagnosis and classification of ALS disease. Non-coding RNA molecules are emerging as the key players in CNS development as well as in the pathogenesis of numerous neurodegenerative diseases. Studying the changes in their spatial and temporal expression in different neuronal and glial cell types, during normal brain development and aging, as well as their aberrant expression in pathological states, will help to pinpoint the molecules that have the potential as biomarkers useful in the diagnosis and prognosis of different disorders, including ALS. The differential expression of the gene, as well as the non-coding RNAs in the blood of ALS patients, and the comparison with their expression during the early mammalian CNS development, could give hints towards the resolution of the origin of the disease.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/ijms231911360/s1>.

Author Contributions: Conceptualization, M.M., D.G., M.R.-G.; methodology, D.G., J.B., I.T., G.J.; resources, M.M., D.G., C.S., G.L.M.; writing—original draft preparation, M.M., D.G., M.R.-G., J.B., C.S., G.L.M.; writing—review and editing, M.R.-G.; supervision, M.M., D.G., M.R.-G. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Slovenian research agency ARRS (research core funding No. P3-0427 and P1-0170), by the Croatian Science Foundation (Hrvatska Zaklada za Znanost; CSF) grant IP-2016-06-7060, the financial support from the University of Rijeka (uniri-biomed-18-258-6427, uniri-prirod-18-290-1463 and uniri-sp-biomed-19-50-1560), and the International Centre for Genetic Engineering and Biotechnology (ICGEB), Grant/Award Number: CRP/CRO14-03. C.S. was supported by the Departamento de Ciencias Naturales (DCN), de la División de Ciencias Naturales e Ingeniería (DCNI) de la UAM-Cuajimalpa. G.L.M. was supported by Universidad Austral, CONICET, and the Ministry of Science, Technology, and Productive Innovation of Argentina through the Fund for Scientific and Technological Research (FONCYT, PICT-2020-SERIEA-00928).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki. Ethical review and approval were waived for this study as all examinations were done as a part of routine diagnostic procedures. The patients provided informed consent for the genetic analysis and publication of their medical information. The animal study was reviewed and approved by the Ethical Committee of the Department of Biotechnology of the University of Rijeka.

Informed Consent Statement: Informed consent was obtained from the subjects involved in the study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Beers, D.R.; Appel, S.H. Immune dysregulation in amyotrophic lateral sclerosis: Mechanisms and emerging therapies. *Lancet Neurol.* **2019**, *18*, 211–220. [[CrossRef](#)]
2. Shaw, P.J. Motor Neurone Disease. *BMJ* **1999**, *318*, 1118–1121. [[CrossRef](#)] [[PubMed](#)]
3. Boillée, S.; Velde, C.V.; Cleveland, D.W. ALS: A Disease of Motor Neurons and Their Nonneuronal Neighbors. *Neuron* **2006**, *52*, 39–59. [[CrossRef](#)] [[PubMed](#)]
4. Rothstein, J.D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. *Ann. Neurol.* **2009**, *65*, S3–S9. [[CrossRef](#)] [[PubMed](#)]
5. Arai, T.; Hasegawa, M.; Akiyama, H.; Ikeda, K.; Nonaka, T.; Mori, H.; Mann, D.; Tsuchiya, K.; Yoshida, M.; Hashizume, Y.; et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Biochem. Biophys. Res. Commun.* **2006**, *351*, 602–611. [[CrossRef](#)]
6. Neumann, M.; Sampathu, D.M.; Kwong, L.K.; Truax, A.C.; Micsenyi, M.C.; Chou, T.T.; Bruce, J.; Schuck, T.; Grossman, M.; Clark, C.M.; et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. *Science* **2006**, *314*, 130–133. [[CrossRef](#)]
7. Sreedharan, J.; Blair, I.P.; Tripathi, V.B.; Hu, X.; Vance, C.; Rogelj, B.; Ackerley, S.; Durnall, J.C.; Williams, K.L.; Buratti, E.; et al. TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis. *Science* **2008**, *319*, 1668–1672. [[CrossRef](#)]
8. Morgan, S.; Orrell, R.W. Pathogenesis of amyotrophic lateral sclerosis. *Br. Med. Bull.* **2016**, *119*, 87–98. [[CrossRef](#)]
9. Vucic, S. Pathophysiology of Neurodegeneration in Familial Amyotrophic Lateral Sclerosis. *Curr. Mol. Med.* **2009**, *9*, 255–272. [[CrossRef](#)]
10. Pagani, M.R.; Gonzalez, L.E.; Uchitel, O.D. Autoimmunity in Amyotrophic Lateral Sclerosis: Past and Present. *Neurol. Res. Int.* **2011**, *2011*, 497080. [[CrossRef](#)]
11. Petrov, D.; Mansfield, C.; Moussy, A.; Hermine, O. ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? *Front. Aging Neurosci.* **2017**, *9*, 68. [[CrossRef](#)]
12. Sawada, H. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. *Expert Opin. Pharmacother.* **2017**, *18*, 735–738. [[CrossRef](#)] [[PubMed](#)]
13. Amado, D.A.; Davidson, B.L. Gene therapy for ALS: A review. *Mol. Ther.* **2021**, *29*, 3345–3358. [[CrossRef](#)] [[PubMed](#)]
14. Kim, G.; Gautier, O.; Tassoni-Tsuchida, E.; Ma, X.R.; Gitler, A.D. ALS Genetics: Gains, Losses, and Implications for Future Therapies. *Neuron* **2020**, *108*, 822–842. [[CrossRef](#)] [[PubMed](#)]
15. Kiernan, M.C.; Vucic, S.; Talbot, K.; McDermott, C.J.; Hardiman, O.; Shefner, J.M.; Al-Chalabi, A.; Huynh, W.; Cudkowicz, M.; Talman, P.; et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. *Nat. Rev. Neurol.* **2020**, *17*, 104–118. [[CrossRef](#)]

16. van Rheenen, W.; van der Spek, R.A.A.; Bakker, M.K.; van Vugt, J.J.F.A.; Hop, P.J.; Zwamborn, R.A.J.; de Klein, N.; Westra, H.-J.; Bakker, O.B.; Deelen, P.; et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. *Nat. Genet.* **2021**, *53*, 1636–1648. [[CrossRef](#)]
17. Tomljanović, I.; Petrović, A.; Ban, J.; Mladinic, M. Proteomic analysis of opossum *Monodelphis domestica* spinal cord reveals the changes of proteins related to neurodegenerative diseases during developmental period when neuroregeneration stops being possible. *Biochem. Biophys. Res. Commun.* **2021**, *587*, 85–91. [[CrossRef](#)]
18. Gentile, G.; Morello, G.; La Cognata, V.; Guarnaccia, M.; Conforti, F.L.; Cavallaro, S. Dysregulated miRNAs as Biomarkers and Therapeutical Targets in Neurodegenerative Diseases. *J. Pers. Med.* **2022**, *12*, 770. [[CrossRef](#)]
19. Ravnik-Glavač, M.; Glavač, D. Circulating RNAs as Potential Biomarkers in Amyotrophic Lateral Sclerosis. *Int. J. Mol. Sci.* **2020**, *21*, 1714. [[CrossRef](#)]
20. Leblond, C.S.; Kaneb, H.M.; Dion, P.A.; Rouleau, G.A. Dissection of genetic factors associated with amyotrophic lateral sclerosis. *Exp. Neurol.* **2014**, *262*, 91–101. [[CrossRef](#)]
21. Deng, H.X.; Chen, W.; Hong, S.T.; Boycott, K.M.; Gorrie, G.H.; Siddique, N.; Yang, Y.; Fecto, F.; Shi, Y.; Zhai, H.; et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. *Nature* **2011**, *477*, 211–215. [[CrossRef](#)] [[PubMed](#)]
22. Siddique, T.; Pericak-Vance, M.A.; Brooks, B.R.; Roos, R.P.; Hung, W.-Y.; Antel, J.P.; Munsat, T.L.; Phillips, K.; Warner, K.; Speer, M.; et al. Linkage analysis in familial amyotrophic lateral sclerosis. *Neurology* **1989**, *39*, 919. [[CrossRef](#)] [[PubMed](#)]
23. Rosen, D.R.; Siddique, T.; Patterson, D.; Figlewicz, D.A.; Sapp, P.; Hentati, A.; Donaldson, D.; Goto, J.; O'Regan, J.P.; Deng, H.-X.; et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. *Nature* **1993**, *362*, 59–62. [[CrossRef](#)] [[PubMed](#)]
24. Kwiatkowski, T.J., Jr.; Bosco, D.A.; Leclerc, A.L.; Tamrazian, E.; Vandenburg, C.R.; Russ, C.; Davis, A.; Gilchrist, J.; Kasarskis, E.J.; Munsat, T.; et al. Mutations in the FUS/TLS Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis. *Science* **2009**, *323*, 1205–1208. [[CrossRef](#)]
25. Vance, C.; Rogelj, B.; Hortobágyi, T.; De Vos, K.J.; Nishimura, A.L.; Sreedharan, J.; Hu, X.; Smith, B.; Ruddy, D.; Wright, P.; et al. Mutations in FUS, an RNA Processing Protein, Cause Familial Amyotrophic Lateral Sclerosis Type 6. *Science* **2009**, *323*, 1208–1211. [[CrossRef](#)]
26. Kabashi, E.; Valdmanis, P.; Dion, P.; Spiegelman, D.; McConkey, B.J.; Velde, C.V.; Bouchard, J.-P.; Lacomblez, L.; Pochigaeva, K.; Salachas, F.; et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. *Nat. Genet.* **2008**, *40*, 572–574. [[CrossRef](#)]
27. Van Deerlin, V.M.; Leverenz, J.B.; Bekris, L.M.; Bird, T.D.; Yuan, W.; Elman, L.B.; Clay, D.; Wood, E.M.; Chen-Plotkin, A.S.; Martinez-Lage, M.; et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: A genetic and histopathological analysis. *Lancet Neurol.* **2008**, *7*, 409–416. [[CrossRef](#)]
28. DeJesus-Hernandez, M.; Mackenzie, I.R.; Boeve, B.F.; Boxer, A.L.; Baker, M.; Rutherford, N.J.; Nicholson, A.M.; Finch, N.A.; Flynn, H.; Adamson, J.; et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. *Neuron* **2011**, *72*, 245–256. [[CrossRef](#)]
29. Renton, A.E.; Majounie, E.; Waite, A.; Simon-Saánchez, J.; Rollinson, S.; Gibbs, J.R.; Schymick, J.C.; Laaksovirta, H.; van Swieten, J.C.; Myllykangas, L.; et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. *Neuron* **2011**, *72*, 257–268. [[CrossRef](#)]
30. Millecamps, S.; Boillée, S.; Le Ber, I.; Seilhean, D.; Teyssou, E.; Giraudeau, M.; Moigneu, C.; Vandenberghe, N.; Danel-Brunaud, V.; Corcia, P.; et al. Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. *J. Med. Genet.* **2012**, *49*, 258–263. [[CrossRef](#)]
31. Wijesekera, L.C.; Leigh, P.N. Amyotrophic lateral sclerosis. *Orphanet J. Rare Dis.* **2009**, *4*, 3. [[CrossRef](#)] [[PubMed](#)]
32. Andersen, P.M.; Al-Chalabi, A. Clinical genetics of amyotrophic lateral sclerosis: What do we really know? *Nat. Rev. Neurol.* **2011**, *7*, 603–615. [[CrossRef](#)] [[PubMed](#)]
33. Renton, A.E.; Chio, A.; Traynor, B.J. State of play in amyotrophic lateral sclerosis genetics. *Nat. Neurosci.* **2013**, *17*, 17–23. [[CrossRef](#)] [[PubMed](#)]
34. Tsuji, S. The Neurogenomics View of Neurological Diseases. *JAMA Neurol.* **2013**, *70*, 689–694. [[CrossRef](#)] [[PubMed](#)]
35. Li, T.M.; Alberman, E.; Swash, M. Comparison of sporadic and familial disease amongst 580 cases of motor neuron disease. *J. Neurol. Neurosurg. Psychiatry* **1988**, *51*, 778–784. [[CrossRef](#)]
36. Strong, M.; Hudson, A.; Alvord, W. Familial Amyotrophic Lateral Sclerosis, 1850-1989: A Statistical Analysis of the World Literature. *Can. J. Neurol. Sci.* **1991**, *18*, 45–58. [[CrossRef](#)]
37. Liscic, R.M.; Grinberg, L.; Zidar, J.; Gitcho, M.A.; Cairns, N.J. ALS and FTL D: Two faces of TDP-43 proteinopathy. *Eur. J. Neurol.* **2008**, *15*, 772–780. [[CrossRef](#)]
38. Byrne, S.C.; Walsh, C.; Lynch, C.; Bede, P.; Elamin, M.; Kenna, K.; McLaughlin, R.; Hardiman, O. Rate of familial amyotrophic lateral sclerosis: A systematic review and meta-analysis. *J. Neurol. Neurosurg. Psychiatry* **2010**, *82*, 623–627. [[CrossRef](#)]
39. Cerami, C.; Scarpini, E.; Cappa, S.; Galimberti, D. Frontotemporal lobar degeneration: Current knowledge and future challenges. *J. Neurol.* **2012**, *259*, 2278–2286. [[CrossRef](#)]
40. Maruyama, H.; Morino, H.; Ito, H.; Izumi, Y.; Kato, H.; Watanabe, Y.; Kinoshita, Y.; Kamada, M.; Nodera, H.; Suzuki, H.; et al. Mutations of optineurin in amyotrophic lateral sclerosis. *Nature* **2010**, *465*, 223–226. [[CrossRef](#)]

41. Johnson, J.O.; Mandrioli, J.; Benatar, M.; Abramzon, Y.; Van Deerlin, V.M.; Trojanowski, J.Q.; Gibbs, J.R.; Brunetti, M.; Gronka, S.; Wu, J.; et al. Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS. *Neuron* **2010**, *68*, 857–864. [[CrossRef](#)] [[PubMed](#)]
42. Koppers, M.; Groen, E.J.; van Vught, P.W.; van Rheenen, W.; Witteveen, E.; van Es, M.A.; Pasterkamp, R.J.; Berg, L.H.V.D.; Veldink, J.H. Screening for rare variants in the coding region of ALS-associated genes at 9p21.2 and 19p13.3. *Neurobiol. Aging* **2013**, *34*, 1518.e5–1518.e7. [[CrossRef](#)]
43. Fecto, F.; Yan, J.; Vemula, S.P.; Liu, E.; Yang, Y.; Chen, W.; Zheng, J.G.; Shi, Y.; Siddique, N.; Arrat, H.; et al. SQSTM1 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis. *Arch. Neurol.* **2011**, *68*, 1440–1446. [[CrossRef](#)] [[PubMed](#)]
44. Chow, C.Y.; Landers, J.E.; Bergren, S.K.; Sapp, P.C.; Grant, A.E.; Jones, J.M.; Everett, L.; Lenk, G.M.; McKenna-Yasek, D.M.; Weisman, L.S.; et al. Deleterious Variants of FIG4, a Phosphoinositide Phosphatase, in Patients with ALS. *Am. J. Hum. Genet.* **2009**, *84*, 85–88. [[CrossRef](#)] [[PubMed](#)]
45. Elden, A.C.; Kim, H.-J.; Hart, M.P.; Chen-Plotkin, A.S.; Johnson, B.S.; Fang, X.; Armarkola, M.; Geser, F.; Greene, R.; Lu, M.M.; et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. *Nature* **2010**, *466*, 1069–1075. [[CrossRef](#)]
46. Mitchell, J.; Paul, P.; Chen, H.-J.; Morris, A.; Payling, M.; Falchi, M.; Habgood, J.; Panoutsou, S.; Winkler, S.; Tisato, V.; et al. Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 7556–7561. [[CrossRef](#)]
47. Orlacchio, A.; Babalini, C.; Borreca, A.; Patrono, C.; Massa, R.; Basaran, S.; Munhoz, R.P.; Rogaeva, E.A.; St George-Hyslop, P.H.; Bernardi, G.; et al. SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. *Brain* **2010**, *133*, 591–598. [[CrossRef](#)]
48. Wu, C.-H.; Fallini, C.; Ticozzi, N.; Keagle, P.J.; Sapp, P.C.; Piotrowska, K.; Lowe, P.; Koppers, M.; McKenna-Yasek, D.; Baron, D.M.; et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. *Nature* **2012**, *488*, 499–503. [[CrossRef](#)]
49. Nishimura, A.L.; Mitne-Neto, M.; Silva, H.C.; Richieri-Costa, A.; Middleton, S.; Cascio, D.; Kok, F.; Oliveira, J.R.; Gillingwater, T.; Webb, J.; et al. A Mutation in the Vesicle-Trafficking Protein VAPB Causes Late-Onset Spinal Muscular Atrophy and Amyotrophic Lateral Sclerosis. *Am. J. Hum. Genet.* **2004**, *75*, 822–831. [[CrossRef](#)]
50. Yang, Y.; Hentati, A.; Deng, H.-X.; Dabbagh, O.; Sasaki, T.; Hirano, M.; Hung, W.-Y.; Ouahchi, K.; Yan, J.; Azim, A.C.; et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. *Nat. Genet.* **2001**, *29*, 160–165. [[CrossRef](#)]
51. Chen, Y.-Z.; Bennett, C.L.; Huynh, H.M.; Blair, I.P.; Puls, I.; Irobi, J.; Dierick, I.; Abel, A.; Kennerson, M.L.; Rabin, B.A.; et al. DNA/RNA Helicase Gene Mutations in a Form of Juvenile Amyotrophic Lateral Sclerosis (ALS4). *Am. J. Hum. Genet.* **2004**, *74*, 1128–1135. [[CrossRef](#)] [[PubMed](#)]
52. Greenway, M.J.; Andersen, P.M.; Russ, C.; Ennis, S.; Cashman, S.; Donaghy, C.; Patterson, V.; Swingler, R.; Kieran, D.; Prehn, J.; et al. ANG mutations segregate with familial and ‘sporadic’ amyotrophic lateral sclerosis. *Nat. Genet.* **2006**, *38*, 411–413. [[CrossRef](#)] [[PubMed](#)]
53. Freischmidt, A.; Wieland, T.; Richter, B.; Ruf, W.P.; Schaeffer, V.; Müller, K.; Marroquin, N.; Nordin, F.; Hübers, A.; Weydt, P.; et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. *Nat. Neurosci.* **2015**, *18*, 631–636. [[CrossRef](#)] [[PubMed](#)]
54. Brenner, D.; Yilmaz, R.; Müller, K.; Grehl, T.; Petri, S.; Meyer, T.; Grosskreutz, J.; Weydt, P.; Ruf, W.; Neuwirth, C.; et al. Hot-spot KIF5A mutations cause familial ALS. *Brain* **2018**, *141*, 688–697. [[CrossRef](#)]
55. Nicolas, A.; Kenna, K.P.; Renton, A.E.; Ticozzi, N.; Faghri, F.; Chia, R.; Dominov, J.A.; Kenna, B.J.; Nalls, M.A.; Keagle, P.; et al. Genome-wide analyses identify KIF5A as a novel ALS gene. *Neuron* **2018**, *97*, 1268–1283.e6. [[CrossRef](#)]
56. van Rheenen, W.; Shatunov, A.; Dekker, A.M.; McLaughlin, R.L.; Diekstra, F.P.; Pulit, S.L.; van der Spek, R.A.A.; Vösa, U.; de Jong, S.; Robinson, M.R.; et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. *Nat. Genet.* **2016**, *48*, 1043–1048. [[CrossRef](#)]
57. Morahan, J.M.; Yu, B.; Trent, R.J.; Pamphlett, R. A genome-wide analysis of brain DNA methylation identifies new candidate genes for sporadic amyotrophic lateral sclerosis. *Amyotroph. Lateral Scler.* **2009**, *10*, 418–429. [[CrossRef](#)]
58. Figueroa-Romero, C.; Hur, J.; Bender, D.E.; Delaney, C.E.; Cataldo, M.D.; Smith, A.L.; Yung, R.; Ruden, D.M.; Callaghan, B.C.; Feldman, E.L. Identification of Epigenetically Altered Genes in Sporadic Amyotrophic Lateral Sclerosis. *PLoS ONE* **2012**, *7*, e52672. [[CrossRef](#)]
59. Xi, Z.; Zinman, L.; Moreno, D.; Schymick, J.; Liang, Y.; Sato, C.; Zheng, Y.; Ghani, M.; Dib, S.; Keith, J.; et al. Hypermethylation of the CpG Island Near the G4C2 Repeat in ALS with a C9orf72 Expansion. *Am. J. Hum. Genet.* **2013**, *92*, 981–989. [[CrossRef](#)]
60. Chestnut, B.A.; Chang, Q.; Price, A.; Lesuisse, C.; Wong, M.; Martin, L.J. Epigenetic Regulation of Motor Neuron Cell Death through DNA Methylation. *J. Neurosci.* **2011**, *31*, 16619–16636. [[CrossRef](#)]
61. Doroszkiewicz, J.; Groblewska, M.; Mroczko, B. Molecular Biomarkers and Their Implications for the Early Diagnosis of Selected Neurodegenerative Diseases. *Int. J. Mol. Sci.* **2022**, *23*, 4610. [[CrossRef](#)] [[PubMed](#)]
62. Chen, W.; Guo, L.; Li, M.; Wei, C.; Li, S.; Xu, R. The pathogenesis of amyotrophic lateral sclerosis: Mitochondrial dysfunction, protein misfolding and epigenetics. *Brain Res.* **2022**, *1786*, 147904. [[CrossRef](#)] [[PubMed](#)]
63. Zhou, S.; Yu, X.; Wang, M.; Meng, Y.; Song, D.; Yang, H.; Wang, D.; Bi, J.; Xu, S. Long Non-coding RNAs in Pathogenesis of Neurodegenerative Diseases. *Front. Cell Dev. Biol.* **2021**, *9*, 719247. [[CrossRef](#)] [[PubMed](#)]

64. Bartel, D.P. Metazoan MicroRNAs. *Cell* **2018**, *173*, 20–51. [[CrossRef](#)] [[PubMed](#)]
65. Kocerha, J.; Kouri, N.; Baker, M.; Finch, N.; DeJesus-Hernandez, M.; Gonzalez, J.; Chidamparam, K.; A Josephs, K.; Boeve, B.F.; Graff-Radford, N.R.; et al. Altered microRNA expression in frontotemporal lobar degeneration with TDP-43 pathology caused by progranulin mutations. *BMC Genom.* **2011**, *12*, 527. [[CrossRef](#)]
66. Chen, Y.; Wei, Q.; Chen, X.; Li, C.; Cao, B.; Ou, R.; Hadano, S.; Shang, H.-F. Aberration of miRNAs Expression in Leukocytes from Sporadic Amyotrophic Lateral Sclerosis. *Front. Mol. Neurosci.* **2016**, *9*, 69. [[CrossRef](#)]
67. Waller, R.; Goodall, E.F.; Milo, M.; Cooper-Knock, J.; Da Costa, M.; Hobson, E.; Kazoka, M.; Wollff, H.; Heath, P.R.; Shaw, P.J.; et al. Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS). *Neurobiol. Aging* **2017**, *55*, 123–131. [[CrossRef](#)]
68. Matamala, J.M.; Arias-Carrasco, R.; Sanchez, C.; Uhrig, M.; Bargsted, L.; Matus, S.; Maracaja-Coutinho, V.; Abarzua, S.; van Zundert, B.; Verdugo, R.; et al. Genome-wide circulating microRNA expression profiling reveals potential biomarkers for amyotrophic lateral sclerosis. *Neurobiol. Aging* **2018**, *64*, 123–138. [[CrossRef](#)]
69. Ricci, C.; Marzocchi, C.; Battistini, S. MicroRNAs as Biomarkers in Amyotrophic Lateral Sclerosis. *Cells* **2018**, *7*, 219. [[CrossRef](#)]
70. Joilin, G.; Leigh, P.N.; Newbury, S.F.; Hafezparast, M. An Overview of MicroRNAs as Biomarkers of ALS. *Front. Neurol.* **2019**, *10*, 186. [[CrossRef](#)]
71. Laneve, P.; Tollis, P.; Caffarelli, E. RNA Deregulation in Amyotrophic Lateral Sclerosis: The Noncoding Perspective. *Int. J. Mol. Sci.* **2021**, *22*, 10285. [[CrossRef](#)] [[PubMed](#)]
72. Nguyen, T.P.N.; Kumar, M.; Fedele, E.; Bonanno, G.; Bonifacino, T. MicroRNA Alteration, Application as Biomarkers, and Therapeutic Approaches in Neurodegenerative Diseases. *Int. J. Mol. Sci.* **2022**, *23*, 4718. [[CrossRef](#)] [[PubMed](#)]
73. Liu, J.; Zhou, F.; Guan, Y.; Meng, F.; Zhao, Z.; Su, Q.; Bao, W.; Wang, X.; Zhao, J.; Huo, Z.; et al. The Biogenesis of miRNAs and Their Role in the Development of Amyotrophic Lateral Sclerosis. *Cells* **2022**, *11*, 572. [[CrossRef](#)] [[PubMed](#)]
74. Wan, P.; Su, W.; Zhuo, Y. The Role of Long Noncoding RNAs in Neurodegenerative Diseases. *Mol. Neurobiol.* **2016**, *54*, 2012–2021. [[CrossRef](#)]
75. Gagliardi, S.; Pandini, C.; Garofalo, M.; Bordoni, M.; Pansarasa, O.; Cereda, C. Long non coding RNAs and ALS: Still much to do. *Non-Coding RNA Res.* **2018**, *3*, 226–231. [[CrossRef](#)] [[PubMed](#)]
76. Gagliardi, S.; Zucca, S.; Pandini, C.; Diamanti, L.; Bordoni, M.; Sproviero, D.; Arigoni, M.; Olivero, M.; Pansarasa, O.; Ceroni, M.; et al. Long non-coding and coding RNAs characterization in Peripheral Blood Mononuclear Cells and Spinal Cord from Amyotrophic Lateral Sclerosis patients. *Sci. Rep.* **2018**, *8*, 2378. [[CrossRef](#)]
77. Suzuki, H.; Shibagaki, Y.; Hattori, S.; Matsuoka, M. C9-ALS/FTD-linked proline–arginine dipeptide repeat protein associates with paraspeckle components and increases paraspeckle formation. *Cell Death Dis.* **2019**, *10*, 1–16. [[CrossRef](#)]
78. Vangoor, V.R.; Gomes-Duarte, A.; Pasterkamp, R.J. Long non-coding RNAs in motor neuron development and disease. *J. Neurochem.* **2020**, *156*, 777–801. [[CrossRef](#)]
79. Yu, Y.; Pang, D.; Li, C.; Gu, X.; Chen, Y.; Ou, R.; Wei, Q.; Shang, H. The expression discrepancy and characteristics of long non-coding RNAs in peripheral blood leukocytes from amyotrophic lateral sclerosis patients. *Mol. Neurobiol.* **2022**, *59*, 3678–3689. [[CrossRef](#)]
80. Varadarajan, S.G.; Hunyara, J.L.; Hamilton, N.R.; Kolodkin, A.L.; Huberman, A.D. Central nervous system regeneration. *Cell* **2022**, *185*, 77–94. [[CrossRef](#)]
81. Mladinic, M.; Muller, K.J.; Nicholls, J.G. Central nervous system regeneration: From leech to opossum. *J. Physiol.* **2009**, *587*, 2775–2782. [[CrossRef](#)] [[PubMed](#)]
82. Nicholls, J.; Saunders, N. Regeneration of immature mammalian spinal cord after injury. *Trends Neurosci.* **1996**, *19*, 229–234. [[CrossRef](#)]
83. Nicholls, J.G.; Stewart, R.R.; Erulkar, S.D.; Saunders, N. Reflexes, fictive respiration and cell division in the brain and spinal cord of the newborn opossum, *Monodelphis domestica*, isolated and maintained in vitro. *J. Exp. Biol.* **1990**, *152*, 1–15. [[CrossRef](#)] [[PubMed](#)]
84. Tran, A.P.; Warren, P.M.; Silver, J. The Biology of Regeneration Failure and Success after Spinal Cord Injury. *Physiol. Rev.* **2018**, *98*, 881–917. [[CrossRef](#)]
85. Cardoso-Moreira, M.; Halbert, J.; Valloton, D.; Velten, B.; Chen, C.; Shao, Y.; Liechti, A.; Ascensão, K.; Rummel, C.; Ovchinnikova, S.; et al. Gene expression across mammalian organ development. *Nature* **2019**, *571*, 505–509. [[CrossRef](#)]
86. Varga, Z.M.; Bandtlow, C.E.; Eurlkar, S.D.; Schwab, M.E.; Nicholls, J.G. The Critical Period for Repair of CNS of Neonatal Opossum (*Monodelphis domestica*) in Culture: Correlation with Development of Glial Cells, Myelin and Growth-inhibitory Molecules. *Eur. J. Neurosci.* **1995**, *7*, 2119–2129. [[CrossRef](#)]
87. Mladinic, M.; Wintzer, M.; Del Bel, E.; Casseler, C.; Lazarevic, D.; Crovella, S.; Gustincich, S.; Cattaneo, A.; Nicholls, J. Differential Expression of Genes at Stages When Regeneration Can and Cannot Occur after Injury to Immature Mammalian Spinal Cord. *Cell. Mol. Neurobiol.* **2005**, *25*, 407–426. [[CrossRef](#)]
88. Mladinic, M.; Lefèvre, C.; Del Bel, E.; Nicholls, J.; Digby, M. Developmental changes of gene expression after spinal cord injury in neonatal opossums. *Brain Res.* **2010**, *1363*, 20–39. [[CrossRef](#)]
89. Schaefers, A.T.U.; Teuchert-Noodt, G. Developmental neuroplasticity and the origin of neurodegenerative diseases. *World J. Biol. Psychiatry* **2013**, *17*, 797104. [[CrossRef](#)]

90. Fogh, I.; Ratti, A.; Gellera, C.; Lin, K.; Tiloca, C.; Moskvina, V.; Corrado, L.; Soraru, G.; Cereda, C.; Corti, S.; et al. A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. *Hum. Mol. Genet.* **2013**, *23*, 2220–2231. [[CrossRef](#)]
91. van Es, M.; Veldink, J.H.; Saris, C.G.J.; Blauw, H.M.; Van Vught, P.W.J.; Birve, A.; Lemmens, R.; Schelhaas, H.J.; Groen, E.J.; Huisman, M.H.B.; et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. *Nat. Genet.* **2009**, *41*, 1083–1087. [[CrossRef](#)] [[PubMed](#)]
92. Rosenmund, C.; Sigler, A.; Augustin, I.; Reim, K.; Brose, N.; Rhee, J.-S. Differential Control of Vesicle Priming and Short-Term Plasticity by Munc13 Isoforms. *Neuron* **2002**, *33*, 411–424. [[CrossRef](#)]
93. Augustin, I.; Rosenmund, C.; Südhof, T.C.; Brose, N. Munc13-1 is essential for fusion competence of glutamatergic synaptic vesicles. *Nature* **1999**, *400*, 457–461. [[CrossRef](#)] [[PubMed](#)]
94. Puzzolo, E.; Mallamaci, A. Cortico-cerebral histogenesis in the opossum *Monodelphis domestica*: Generation of a hexalaminar neocortex in the absence of a basal proliferative compartment. *Neural Dev.* **2010**, *5*, 8. [[CrossRef](#)] [[PubMed](#)]
95. Guillaud, L.; El-Agamy, S.E.; Otsuki, M.; Terenzio, M. Anterograde Axonal Transport in Neuronal Homeostasis and Disease. *Front. Mol. Neurosci.* **2020**, *13*, 556175. [[CrossRef](#)]
96. Saito, A.; Cavalli, V. Signaling Over Distances. *Mol. Cell. Proteom.* **2016**, *15*, 382–393. [[CrossRef](#)]
97. Setou, M.; Nakagawa, T.; Seog, D.-H.; Hirokawa, N. Kinesin Superfamily Motor Protein KIF17 and mLin-10 in NMDA Receptor-Containing Vesicle Transport. *Science* **2000**, *288*, 1796–1802. [[CrossRef](#)]
98. Kanai, Y.; Okada, Y.; Tanaka, Y.; Harada, A.; Terada, S.; Hirokawa, N. KIF5C, a Novel Neuronal Kinesin Enriched in Motor Neurons. *J. Neurosci.* **2000**, *20*, 6374–6384. [[CrossRef](#)]
99. Buster, D.W.; Baird, D.H.; Yu, W.; Solowska, J.M.; Chauvière, M.; Mazurek, A.; Kress, M.; Baas, P.W. Expression of the mitotic kinesin Kif15 in postmitotic neurons: Implications for neuronal migration and development. *J. Neurocytol.* **2003**, *32*, 79–96. [[CrossRef](#)]
100. Seelke, A.M.; Dooley, J.C.; Krubitzer, L.A. Differential changes in the cellular composition of the developing marsupial brain. *J. Comp. Neurol.* **2013**, *521*, 2602–2620. [[CrossRef](#)]
101. Cirulli, E.T.; Lasseigne, B.N.; Petrovski, S.; Sapp, P.C.; Dion, P.A.; Leblond, C.S.; Couthouis, J.; Lu, Y.-F.; Wang, Q.; Krueger, B.J.; et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. *Science* **2015**, *347*, 1436–1441. [[CrossRef](#)] [[PubMed](#)]
102. Kenna, K.P.; SLAGEN Consortium; van Doormaal, P.T.C.; Dekker, A.M.; Ticozzi, N.; Kenna, B.J.; Diekstra, F.P.; van Rheenen, W.; van Eijk, K.R.; Jones, A.R.; et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. *Nat. Genet.* **2016**, *48*, 1037–1042. [[CrossRef](#)] [[PubMed](#)]
103. Fry, A.M.; O'Regan, L.; Sabir, S.; Bayliss, R. Cell cycle regulation by the NEK family of protein kinases. *J. Cell Sci.* **2012**, *125*, 4423–4433. [[CrossRef](#)] [[PubMed](#)]
104. Meirelles, G.V.; Perez, A.M.; De Souza, E.E.; Basei, F.L.; Papa, P.F.; Hanchuk, T.D.M.; Cardoso, V.B.; Kobarg, J. “Stop Ne(c)king around”: How interactomics contributes to functionally characterize Nek family kinases. *World J. Biol. Chem.* **2014**, *5*, 141–160. [[CrossRef](#)]
105. Petrović, A.; Ban, J.; Ivaničić, M.; Tomljanović, I.; Mladinic, M. The Role of ATF3 in Neuronal Differentiation and Development of Neuronal Networks in Opossum Postnatal Cortical Cultures. *Int. J. Mol. Sci.* **2022**, *23*, 4964. [[CrossRef](#)]
106. Hunt, D.; Raivich, G.; Anderson, P.N. Activating Transcription Factor 3 and the Nervous System. *Front. Mol. Neurosci.* **2012**, *5*, 7. [[CrossRef](#)]
107. Mladinic, M.; Bianchetti, E.; Dekanic, A.; Mazzone, G.L.; Nistri, A. ATF3 is a novel nuclear marker for migrating ependymal stem cells in the rat spinal cord. *Stem Cell Res.* **2014**, *12*, 815–827. [[CrossRef](#)]
108. Chua, J.Y.; Ng, S.J.; Yagensky, O.; Wanker, E.E.; Chua, J.J.E. FEZ1 Forms Complexes with CRMP1 and DCC to Regulate Axon and Dendrite Development. *Eneuro* **2021**, *8*, ENEURO.0193-20.2021. [[CrossRef](#)]
109. Watanabe, Y.; Nakagawa, T.; Akiyama, T.; Nakagawa, M.; Suzuki, N.; Warita, H.; Aoki, M.; Nakayama, K. An Amyotrophic Lateral Sclerosis-Associated Mutant of C21ORF2 Is Stabilized by NEK1-Mediated Hyperphosphorylation and the Inability to Bind FBXO3. *iScience* **2020**, *23*, 101491. [[CrossRef](#)]
110. Chen, J.-L.; Chang, C.-H.; Tsai, J.-W. Gli2 Rescues Delays in Brain Development Induced by Kif3a Dysfunction. *Cereb. Cortex* **2018**, *29*, 751–764. [[CrossRef](#)]
111. Böhme, M.; Beis, C.; Reddy-Alla, S.; Reynolds, E.; Mampell, M.M.; Grasskamp, A.T.; Lützkendorf, J.; Bergeron, D.D.; Driller, J.H.; Babikir, H.; et al. Active zone scaffolds differentially accumulate Unc13 isoforms to tune Ca²⁺ channel-vesicle coupling. *Nat. Neurosci.* **2016**, *19*, 1311–1320. [[CrossRef](#)] [[PubMed](#)]
112. Karlocai, M.R.; Heredi, J.; Benedek, T.; Holderith, N.; Lorincz, A.; Nusser, Z. Variability in the Munc13-1 content of excitatory release sites. *eLife* **2021**, *10*, 67468. [[CrossRef](#)]
113. Armstrong, R.J.; A Barker, R. Neurodegeneration: A failure of neuroregeneration? *Lancet* **2001**, *358*, 1174–1176. [[CrossRef](#)]
114. Poplawski, G.H.D.; Kawaguchi, R.; Van Niekerk, E.; Lu, P.; Mehta, N.; Canete, P.; Lie, R.; Dragatsis, I.; Meves, J.M.; Zheng, B.; et al. Injured adult neurons regress to an embryonic transcriptional growth state. *Nature* **2020**, *581*, 77–82. [[CrossRef](#)]
115. Mertens, J.; Herdy, J.R.; Traxler, L.; Schafer, S.T.; Schlachetzki, J.C.; Böhnke, L.; Reid, D.A.; Lee, H.; Zangwill, D.; Fernandes, D.P.; et al. Age-dependent instability of mature neuronal fate in induced neurons from Alzheimer's patients. *Cell Stem Cell* **2021**, *28*, 1533–1548.e6. [[CrossRef](#)] [[PubMed](#)]

116. Kisby, G.E.; Spencer, P.S. Genotoxic Damage During Brain Development Presages Prototypical Neurodegenerative Disease. *Front. Neurosci.* **2021**, *15*, 752153. [[CrossRef](#)] [[PubMed](#)]
117. Li, P.; Jia, Y.; Tang, W.; Cui, Q.; Liu, M.; Jiang, J. Roles of Non-coding RNAs in Central Nervous System Axon Regeneration. *Front. Neurosci.* **2021**, *15*, 630633. [[CrossRef](#)]
118. Zhao, Y.; Liu, H.; Zhang, Q.; Zhang, Y. The functions of long non-coding RNAs in neural stem cell proliferation and differentiation. *Cell Biosci.* **2020**, *10*, 1–10. [[CrossRef](#)]
119. D’Anca, M.; Buccellato, F.R.; Fenoglio, C.; Galimberti, D. Circular RNAs: Emblematic Players of Neurogenesis and Neurodegeneration. *Int. J. Mol. Sci.* **2022**, *23*, 4134. [[CrossRef](#)]
120. Roy, B.; Lee, E.; Li, T.; Rampersaud, M. Role of miRNAs in Neurodegeneration: From Disease Cause to Tools of Biomarker Discovery and Therapeutics. *Genes* **2022**, *13*, 425. [[CrossRef](#)]
121. Cui, Y.; Yin, Y.; Xiao, Z.; Zhao, Y.; Chen, B.; Yang, B.; Xu, B.; Song, H.; Zou, Y.; Ma, X.; et al. LncRNA Neat1 mediates miR-124-induced activation of Wnt/ β -catenin signaling in spinal cord neural progenitor cells. *Stem Cell Res. Ther.* **2019**, *10*, 1–11. [[CrossRef](#)] [[PubMed](#)]
122. Kang, E.-M.; Jia, Y.-B.; Wang, J.-Y.; Wang, G.-Y.; Chen, H.-J.; Chen, X.-Y.; Ye, Y.-Q.; Zhang, X.; Su, X.-H.; Wang, J.-Y.; et al. Downregulation of MicroRNA-124-3p Promotes Subventricular Zone Neural Stem Cell Activation by Enhancing the Function of BDNF Downstream Pathways after Traumatic Brain Injury in Adult Rats. *CNS Neurosci. Ther.* **2022**, *28*, 1081–1092. [[CrossRef](#)] [[PubMed](#)]
123. Walker, S.E.; Sabin, K.Z.; Gearhart, M.D.; Yamamoto, K.; Echeverri, K. Regulation of stem cell identity by miR-200a during spinal cord regeneration. *Development* **2022**, *149*, 200033. [[CrossRef](#)] [[PubMed](#)]
124. Liu, Y.-P.; Yang, Y.-D.; Mou, F.-F.; Zhu, J.; Li, H.; Zhao, T.-T.; Zhao, Y.; Shao, S.-J.; Cui, G.-H.; Guo, H.-D. Exosome-Mediated miR-21 Was Involved in the Promotion of Structural and Functional Recovery Effect Produced by Electroacupuncture in Sciatic Nerve Injury. *Oxidative Med. Cell. Longev.* **2022**, *2022*, 7530102. [[CrossRef](#)]
125. Li, Z.; Meng, Z.; Zhao, Z. Silk fibroin nanofibrous scaffolds incorporated with microRNA-222 loaded chitosan nanoparticles for enhanced neuronal differentiation of neural stem cells. *Carbohydr. Polym.* **2021**, *277*, 118791. [[CrossRef](#)]
126. Chen, K.; Ding, L.; Shui, H.; Liang, Y.; Zhang, X.; Wang, T.; Li, L.; Liu, S.; Wu, H. MiR-615 Agomir Encapsulated in Pluronic F-127 Alleviates Neuron Damage and Facilitates Function Recovery After Brachial Plexus Avulsion. *J. Mol. Neurosci.* **2021**, *72*, 136–148. [[CrossRef](#)]
127. Wu, H.; Ding, L.; Wang, Y.; Zou, T.-B.; Wang, T.; Fu, W.; Lin, Y.; Zhang, X.; Chen, K.; Lei, Y.; et al. MiR-615 Regulates NSC Differentiation In Vitro and Contributes to Spinal Cord Injury Repair by Targeting LINGO-1. *Mol. Neurobiol.* **2020**, *57*, 3057–3074. [[CrossRef](#)]
128. Zhao, L.; Gong, L.; Li, P.; Qin, J.; Xu, L.; Wei, Q.; Xie, H.; Mao, S.; Yu, B.; Gu, X.; et al. miR-20a Promotes the Axon Regeneration of DRG Neurons by Targeting Nr4a. *Neurosci. Bull.* **2021**, *37*, 569–574. [[CrossRef](#)]
129. Ning, X.-J.; Lu, X.-H.; Luo, J.-C.; Chen, C.; Gao, Q.; Li, Z.-Y.; Wang, H. Molecular mechanism of microRNA-21 promoting Schwann cell proliferation and axon regeneration during injured nerve repair. *RNA Biol.* **2020**, *17*, 1508–1519. [[CrossRef](#)]
130. Cornelis, G.; Souquere, S.; Vernochet, C.; Heidmann, T.; Pierron, G. Functional conservation of the lncRNA NEAT1 in the ancestrally diverged marsupial lineage: Evidence for NEAT1 expression and associated paraspeckle assembly during late gestation in the opossum *Monodelphis domestica*. *RNA Biol.* **2016**, *13*, 826–836. [[CrossRef](#)]
131. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A software environment for integrated models of Biomolecular Interaction Networks. *Genome Res.* **2003**, *13*, 2498–2504. [[CrossRef](#)] [[PubMed](#)]